Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery

International Journal of Pharmaceutics

Volumn 382, Issue 1-2, 2009, Pages 144-150

  Onoue, Satomi ^a   Yamamoto, Kiyoshi ^a   Kawabata, Yohei ^a   Hirose, Mariko ^b   Mizumoto, Takahiro ^b,c   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Ito Life Sciences Inc   (Japan)

^c American Peptide Company   (United States)

Author keywords

Citric acid; Dry powder inhaler; Glucagon; Hyperglycemic effect; Stability

Indexed keywords

CITRIC ACID; DECANOIC ACID; GLUCAGON; LACTATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRY POWDER; GLYCEMIC CONTROL; LUNG ALVEOLUS CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TOXICITY TESTING;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CITRIC ACID; DECANOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; L-LACTATE DEHYDROGENASE; LASERS; MALE; MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; PULMONARY ALVEOLI; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 70350345825     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.08.024     Document Type: Article

References (35)

1. Agu R.U., Ugwoke M.I., Armand M., Kinget R., and Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2 (2001) 198-209
2. Bai J.P., Chang L.L., and Guo J.H. Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon. J. Pharm. Sci. 84 (1995) 1291-1294
3. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Preat V., and Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 92 (2003) 938-950
4. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7 (2005) E20-41
5. Edgerton D.S., Neal D.W., Scott M., Bowen L., Wilson W., Hobbs C.H., Leach C., Sivakumaran S., Strack T.R., and Cherrington A.D. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54 (2005) 1164-1170
6. Endo K., Amikawa S., Matsumoto A., Sahashi N., and Onoue S. Erythritol-based dry powder of glucagon for pulmonary administration. Int. J. Pharm. 290 (2005) 63-71
7. Froment D.P., Molitoris B.A., Buddington B., Miller N., and Alfrey A.C. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int. 36 (1989) 978-984
8. Geary N. Effects of glucagon, insulin, amylin and CGRP on feeding. Neuropeptides 33 (1999) 400-405
9. Gelling R.W., Du X.Q., Dichmann D.S., Romer J., Huang H., Cui L., Obici S., Tang B., Holst J.J., Fledelius C., Johansen P.B., Rossetti L., Jelicks L.A., Serup P., Nishimura E., and Charron M.J. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 1438-1443
10. Hagen J.H. Effect of glucagon on the metabolism of adipose tissue. J. Biol. Chem. 236 (1961) 1023-1027
11. Hirota M., Ikei S., Mishima M., Mori K., Sakamoto K., Yamane T., Idegami K., Katafuchi S., Kiyohara H., Nakashima Y., et al. Glucagon in the metabolic and nutritional management after total pancreatectomy-a case report. Jpn. J. Surg. 19 (1989) 586-592
12. Hooton J.C., Jones M.D., and Price R. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach. J. Pharm. Sci. 95 (2006) 1288-1297
13. Imai T., Sakai M., Ohtake H., Azuma H., and Otagiri M. In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm. Res. 16 (1999) 80-86
14. Karasulu H.Y., Sanal Z.E., Sozer S., Guneri T., and Ertan G. Permeation studies of indomethacin from different emulsions for nasal delivery and their possible anti-inflammatory effects. AAPS PharmSciTech 9 (2008) 342-348
15. Larhrib H., Martin G.P., Marriott C., and Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int. J. Pharm. 257 (2003) 283-296
16. Lee Y.H., Perry B.A., Labruno S., Lee H.S., Stern W., Falzone L.M., and Sinko P.J. Impact of regional intestinal pH modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs. Pharm. Res. 16 (1999) 1233-1239
17. Merrifield R.B. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 32 (1969) 221-296
18. Mochiki E., Suzuki H., Takenoshita S., Nagamachi Y., Kuwano H., Mizumoto A., and Itoh Z. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J. Gastroenterol. 33 (1998) 835-841
19. Onoue S., Hashimoto N., and Yamada S. Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin. Ther. Patents 18 (2008) 429-442
20. Onoue S., Iwasa S., Kojima T., Katoh F., Debari K., Koh K., Matsuda Y., and Yajima T. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J. Chromatogr. A 1109 (2006) 167-173
21. Onoue S., Ohmori Y., Endo K., Yamada S., Kimura R., and Yajima T. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur. J. Biochem. 271 (2004) 1757-1767
22. Onoue S., Ohshima K., Debari K., Koh K., Shioda S., Iwasa S., Kashimoto K., and Yajima T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm. Res. 21 (2004) 1274-1283
23. Onoue S., Waki Y., Hamanaka K., Yajima T., and Kashimoto K. Vasoactive intestinal peptide regulates catecholamine secretion in rat PC12 cells through the pituitary adenylate cyclase activating polypeptide receptor. Biomed. Res. 22 (2001) 77-82
24. Onoue S., Yamada S., and Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 28 (2007) 1640-1650
25. Patton J.S., Fishburn C.S., and Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1 (2004) 338-344
26. Pipeleers D.G., Schuit F.C., in't Veld P.A., Maes E., Hooghe-Peters E.L., Van de Winkel M., and Gepts W. Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology 117 (1985) 824-833
27. Pontiroli A.E., Calderara A., and Pozza G. Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin. Pharmacokinet. 17 (1989) 299-307
28. Rodbell M., Birnbaumer L., Pohl S.L., and Sundby F. The reaction of glucagon with its receptor: evidence for discrete regions of activity and binding in the glucagon molecule. Proc. Natl. Acad. Sci. U.S.A. 68 (1971) 909-913
29. Shah R.B., Palamakula A., and Khan M.A. Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin. J. Pharm. Sci. 93 (2004) 1070-1082
30. Shi M.M., Kugelman A., Iwamoto T., Tian L., and Forman H.J. Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells. J. Biol. Chem. 269 (1994) 26512-26517
31. Sinko P.J., Lee Y.H., Makhey V., Leesman G.D., Sutyak J.P., Yu H., Perry B., Smith C.L., Hu P., Wagner E.J., Falzone L.M., McWhorter L.T., Gilligan J.P., and Stern W. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm. Res. 16 (1999) 527-533
32. Teshima D., Yamauchi A., Makino K., Kataoka Y., Arita Y., Nawata H., and Oishi R. Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int. J. Pharm. 233 (2002) 61-66
33. Todo H., Okamoto H., Iida K., and Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int. J. Pharm. 220 (2001) 101-110
34. Unger R.H., Dobbs R.E., and Orci L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu. Rev. Physiol. 40 (1978) 307-343
35. Zheng X.M., Martin G.P., and Marriott C. Particulate Interactions in Dry Powder Formulations for Inhalation (2001), Taylor & Francis, London